Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | FLT1 | P17948 | 3/20 | 0.40 |
| ▸ | FLT4 | P35916 | 3/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2346880 | 0.93 | KIT (0.50) | KITALOX5IMPDH2MEN1NPC1 | |
| SCHEMBL2348479 | 0.90 | FLT1 (0.46) | KITIMPDH2MEN1NPC1MAPT | |
| SCHEMBL2341934 | 0.89 | IMPDH2 (0.44) | KITIMPDH2MEN1NPC1MAPT | |
| SCHEMBL544079 | 0.87 | NPC1 (0.54) | KITIMPDH2MEN1NPC1MAPT | |
| SCHEMBL2350226 | 0.84 | RAB9A (0.58) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL2346767 | 0.83 | IMPDH2 (0.44) | KITALOX5IMPDH2MEN1NPC1 | |
| SCHEMBL544406 | 0.81 | IMPDH2 (0.62) | KITIMPDH2KDRFLT1FLT4 | |
| SCHEMBL2342462 | 0.78 | NPC1 (0.52) | KITIMPDH2MEN1NPC1MAPT | |
| SCHEMBL543854 | 0.78 | IMPDH2 (0.56) | KITIMPDH2KDRFLT1FLT4 | |
| SCHEMBL10033766 | 0.75 | NPC1 (0.50) | ALOX5IMPDH2MEN1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361624-A1 | Oxazole derivatives and their use as tyrosine kinase inhibitors | AB Science (FR) | 2011-08-31 | — | — | EP | claimed |
| EP-1874305-B1 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2014-08-27 | — | — | EP | disclosed |
| EP-1874305-B1 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2014-08-27 | — | — | EP | disclosed |
| US-8658659-B2 | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2014-02-25 | — | — | US | disclosed |
| US-8658659-B2 | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2014-02-25 | — | — | US | disclosed |
| US-8658659-B2 | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2014-02-25 | — | — | US | disclosed |
| US-20120108616-A1 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AB SCIENCE | 2012-05-03 | — | — | US | disclosed |
| US-20120108616-A1 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AB SCIENCE | 2012-05-03 | — | — | US | disclosed |
| US-20120108616-A1 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AB SCIENCE | 2012-05-03 | — | — | US | disclosed |
| EP-2361624-A1 | Oxazole derivatives and their use as tyrosine kinase inhibitors | AB Science (FR) | 2011-08-31 | — | — | EP | disclosed |
| US-20080242704-A1 | Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors | AB SCIENCE | 2008-10-02 | — | — | US | disclosed |
| US-20080242704-A1 | Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors | AB SCIENCE | 2008-10-02 | — | — | US | disclosed |
| US-20080242704-A1 | Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors | AB SCIENCE | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242704-A1 | Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors | KIT, TYRO3, LCK | KIT 1/4885ALOX5 3096/4885IMPDH2 4112/4885 |
| US-20120108616-A1 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | KIT, FLT3, LTK | KIT 1/4885ALOX5 2289/4885IMPDH2 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.